Fondaparin SodiuM; Fondaparinux Sodium Kev Qhia; Fondaparinux sodium N-4;
Fondaparin SodiuM; Fondaparinux Sodium Kev Qhia; Fondaparinux sodium N-4;
Fondaparinux Kev Ua Txhaum Cai
| Piav | Fondaparinux sodium yog ib qho antithrombin-dependent yam Xa inhibitor. |
| Hais txogPawg | teeb liab txoj kev >> Metabolic enzymes/proteases >> Factor Xa Tshawb xyuas thaj chaw >> Cov kab mob plawv |
| Hom phiaj | Factor Xa[1] |
| Hauv vitrokev kawm | Fondaparinux sodium yog thawj zaug anticoagulant tshiab uas xaiv lub hom phiaj Xa.Rau Fondaparinux, IC50 tus nqi (anti-Xa IU / ml) ntawm activated monocytes (ac-M) yog 0.59 ± 0.05, thiab monocyte-derived particles (MMP) yog 0.17 ± 0.03 [2]. |
| Hauv vivokev tshawb fawb | Fondaparinux sodium muaj linear, koob tshuaj raws li pharmacokinetic profile, uas muab cov lus teb tau zoo.Fondaparinux sodium muaj 100% bioavailability, muaj qhov pib sai, muaj ib nrab-lub neej ntawm 14 mus rau 16 teev, thiab tuaj yeem tiv thaiv thrombosis hauv 24 teev.Cov tshuaj tsis cuam tshuam rau lub sijhawm prothrombin lossis lub sijhawm ua haujlwm ib nrab ntawm thromboplastin, thiab tsis cuam tshuam rau platelet kev ua haujlwm lossis kev sib sau ua ke [1]. |
| Cov ntaub ntawv | [1].Bauer KA.ua al.Fondaparinux sodium: ib qho kev xaiv inhibitor ntawm Factor Xa.Am J Health Syst Pharm.2001 Nov 1;58 Suppl 2:S14-7.[2].Ben-Hadj-Khalifa S, et al.Kev sib txawv coagulation inhibitory nyhuv ntawm fondaparinux, enoxaparin thiab unfractionated heparin hauv cell qauv ntawm thrombin tiam.Ntshav Coagul Fibrinolysis.2011 Jul; 22(5):369-73. |
Cov khoom siv tshuaj thiab lub cev ntawm Fondaparinux
| Cov mis mos molecular | C31H53N3Na10O49S8 |
| Molecular hnyav | 1738.16 Nws |
| PSA | 900.82000 Nws |
Fondaparinux yog ib yam tshiab ntawm cov tshuaj antithrombotic uas tau pom zoo los ntawm FDA tom qab heparin thiab qis molecular hnyav heparin rau kev kho thiab tiv thaiv ntau yam arteriovenous thrombosis.
Cov Lus Qhia: Fondaparinux yog siv rau cov neeg mob uas tau phais loj orthopedic ntawm cov ceg qis, xws li pob txha pob txha, kev phais hauv caug loj lossis hloov lub duav, txhawm rau tiv thaiv venous thromboembolism.Nws yog siv rau kev kho mob ntawm cov neeg mob uas tsis ruaj tsis khov angina los yog non-ST-segment elevation myocardial infarction uas tau mob ceev (<120 feeb) invasive treatment (PCI) yam tsis tau qhia.Nws yog siv rau kev kho mob ntawm cov neeg mob nrog ST-segment elevation myocardial infarction uas siv thrombolysis los yog pib tsis tau txais lwm hom kev kho reperfusion.
1) Glaxo txoj kev lag luam txuas ntxiv yuav muab tso rau hauv cov tshuaj tseem ceeb hauv txoj kev kho mob tom ntej ntawm Ministry of Health, kev hloov kho tus nqi ntawm National Development thiab Reform Commission, thiab kev pov hwm kho mob ntawm Ministry of People Insurance.
A, Cov khoom tseem tsis tau nkag mus rau hauv kev pov hwm kho mob hauv tebchaws.Xyoo 2010, kev kho mob kho mob kho mob tau txais kev pov hwm kho mob hauv zos ntawm 16 lub xeev.Kev muag khoom yog nyob rau hauv thawj theem thiab yuav maj mam hloov lub lag luam uas tsis muaj molecular-hnyav heparin;Kev tuav pov hwm kho mob xeev: Shaanxi, Shanxi, Inner Mongolia, Liaoning, Tibet, Yunnan, Guangdong, Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.
B 、 Cov lus qhia tseem nce ntxiv.GSK tam sim no muaj 3 qhov qhia hauv tsev kho mob.Piv txwv li, cov lus qhia rau stents tsuas yog pom zoo.Lwm yam heparins tsis muaj.Kev siv tshuaj kho mob ntawm stents nce 30% txhua xyoo.Nrog rau kev pom zoo ntawm cov lus qhia tshiab, kev muag khoom yuav nce ntxiv.Hauv kev xav, txhua yam kab mob kho los ntawm heparin series khoom tuaj yeem kho los ntawm cov khoom no.
C 、 Tus nqi kom zoo dua, tus nqi qis kawg ntawm cov khoom no hauv Asmeskas kev lag luam yog 132 US las txhua, hauv Suav teb yog 168 yuan, tus nqi hauv tsev yuav tsis poob.Yog tias koj ua export, lub lag luam thoob ntiaj teb muaj qhov chaw dav;
2) Cov txheej txheem thev naus laus zis yog siab, cov khoom siv raw yog tsim los ntawm 75 kauj ruam, thiab patent tau tas sij hawm rau 5 xyoo (kab lus hauv 2014).Nws tsis tau pom zoo los ntawm lwm cov tuam ntxhab.Lub synthesis yog qhov nyuaj heev.Nws yuav tsis ua tiav hauv tsawg dua 10 xyoo.Lub voj voog yog ntev, nyuaj, thiab peev.siab.Muaj ob peb tus neeg sib tw hauv tebchaws, thiab cov neeg sib tw txawv teb chaws muaj cov nqi raw khoom siab.Peb lub hom phiaj yog kom txo qis cov nqi raw khoom thiab hloov Glaxo hauv cov khoom siv raw khoom.
Hengrui Pharmaceuticals Fondaparinux tau pom zoo ua thawj coj hauv Suav teb 2018.
Guangdong Runxing Biotechnology Co., Ltd. muaj txhua xyoo tso zis ntawm 210 kg ntawm fondaparinux sodium advanced intermediate N3, uas yuav tsum tau ua nyob rau hauv 2018.
Fondaparinux yog thawj zaug tsim los ntawm MYLAN IRELAND.Tam sim no, Hengrui Pharmaceuticals, Borui Pharmaceuticals, Haisco.
JIN DUN Medical muajISO tsim nyog thiab ua tau raws li GMP cov qauv tsim, ua hauj lwm hauv tsev thiab txawv teb chaws cov kws kho tshuaj synthesis nrog kev nplua nuj los coj lub tuam txhab R & D.
TECHNOL OGY ADVANTAGES
● High Pressure Catalytic Hydrogenation .High Pressure Hydrogenolysis Reaction.Cryogenic cov tshuaj tiv thaiv (<-78% C)
●Aromatic Heterocyclic Synthesis
● Kev Ruaj Ntseg Tsis Zoo
● Chiral Resolution
●Heck, Suzuki, Negishi, Sonogashira .Gignard Reaction
Cov khoom siv
Peb lub Lab muaj ntau yam kev sim thiab ntsuas cov cuab yeej, xws li: NMR (Bruker 400M), HPLC, chiral-HPLC, LC-MS, LC-MS/MS (API 4000), IR, UV, GC, GC-MS, Chromatography, Microwave Synthesizer, Parallel Synthesizer, Differential Scanning Calorimeter (DSC), Electron Microscope ...
Pab neeg R&D
Jindun Kev Kho Mob muaj ib pab pawg kws tshaj lij R & D cov neeg ua haujlwm, thiab ntiav ntau tus kws tshaj lij kev siv tshuaj hauv tsev thiab txawv teb chaws los coj R&D, ua rau peb cov khoom sib xyaw ua kom raug thiab ua tau zoo.
Peb tau pab ntau lub tuam txhab tshuaj hauv tsev sab saum toj, xws liHansoh, Hengrui thiab HEC Pharm.Ntawm no peb yuav qhia ib feem ntawm lawv.
Customzation Case Ib:
CAS Nr .: 110351-94-5
Customzation Case Ob:
CAS Nr .: 144848-24-8
Customzation Case Peb:
CAS Nr .: 200636-54-0
1.Customize New Intermediates lossis APIs.Ib yam li cov ntaub ntawv sib qhia saum toj no, cov neeg siv khoom muaj qhov xav tau tshwj xeeb Intermediates lossis APIs, thiab lawv nrhiav tsis tau cov khoom xav tau hauv khw, ces peb tuaj yeem pab kho.
2.Txheej txheem Optimization rau cov khoom qub.Peb pab neeg yuav pab Optimize thiab txhim kho xws li ntau lawm uas nws cov tshuaj tiv thaiv txoj kev yog qub, ntau lawm nqi yog siab, thiab efficiency yog tsawg.Peb tuaj yeem muab cov ntaub ntawv tag nrho rau kev hloov pauv thev naus laus zis thiab kev txhim kho cov txheej txheem, pab cov neeg siv khoom kom muaj txiaj ntsig ntau dua.
Los ntawm cov hom phiaj tshuaj rau INDs, JIN DUN Kev Kho Mob muab rau kojib-nres tus kheej R & D kev daws teeb meem.
JIN DUN Kev Kho Mob hais kom tsim ib pab neeg nrog kev npau suav, ua cov khoom muaj txiaj ntsig, ua kom zoo, nruj, thiab tawm mus ua ib tus neeg ntseeg siab thiab phooj ywg ntawm cov neeg siv khoom!
